Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...

Oppenheimer upgraded Dyne Therapeutics (DYN) on Wednesday, citing a positive read-through from data that Novartis’ (NVS) buyout target Avidity Biosciences (RNA) is set to release this year from a late ...

Expression Therapeutics Inc., a clinical-stage biopharmaceutical company developing next-generation cellular therapies, has appointed David F. Townson, Ph.D., as Chief Executive Officer, effective ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...

New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13 ...

The collaboration pairs Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s deep expertise in immuno-dermatology to identify, validate, and advance ...

Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

Relation Therapeutics Ltd. will collaborate with Novartis AG in a $1.7 billion deal to develop multiple programs to find and advance targets for treating atopic diseases caused by immune dysregulation ...

Through “My Cause My Cleats,” Tyler Smith raises cancer awareness with survivor-designed cleats and a personal tribute to his ...

Cuban attributes the US’ high drug prices to PBMs—often considered the “middlemen” within the pharma supply chain—arguing ...